Literature DB >> 26586646

Lipoarabinomannan, and its related glycolipids, induce divergent and opposing immune responses to Mycobacterium tuberculosis depending on structural diversity and experimental variations.

Gunilla Källenius1, Margarida Correia-Neves2, Helen Buteme3, Beston Hamasur4, Stefan B Svenson4.   

Abstract

Exposure to Mycobacterium tuberculosis (Mtb) may lead to active or latent tuberculosis, or clearance of Mtb, depending essentially on the quality of the host's immune response. This response is initiated through the interaction of Mtb cell wall surface components, mostly glycolipids, with cells of the innate immune system, particularly macrophages (Mφs) and dendritic cells (DCs). The way Mφs and DC alter their cytokine secretome, activate or inhibit different microbicidal mechanisms and present antigens and consequently trigger the T cell-mediated immune response impacts the host immune response against Mtb. Lipoarabinomannan (LAM) is one of the major cell wall components of Mtb. Mannosyl-capped LAM (ManLAM), and its related cell wall-associated types of glycolipids/lipoglycans, namely phosphatidylinositol mannosides (PIMs) and lipomannan (LM), exhibit important and distinct immunomodulatory properties. The structure, internal heterogeneity and abundance of these molecules vary between Mtb strains exhibiting distinct degrees of virulence. Thus ManLAM, LM and PIMs may be considered crucial Mtb-associated virulence factors in the pathogenesis of tuberculosis. Of particular relevance for this review, there is controversy about the specific immunomodulatory properties of these distinct glycolipids, particularly when tested as purified molecules in vitro. In addition to the variability in the glycolipid composition conflicting reports may also result from differences in the protocols used for glycolipid isolation and for in vitro experiments including immune cell types and procedures to generate them. Understanding the immunomodulatory properties of these cell wall glycolipids, how they differ between distinct Mtb strains, and how they influence the degree of Mtb virulence, is of utmost relevance to understand how the host mounts a protective or otherwise pathologic immune response. This is essential for the design of preventive strategies against tuberculosis. Thus, since clarifying the controversy on this matter is crucial we here review, summarize and discuss reported data from in vitro stimulation with the three major Mtb complex cell wall glycolipids (ManLAM, PIMs and LM) in an attempt to conciliate the conflicting findings.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glycolipids; Lipoarabinomannan; Mycobacterium; Tuberculosis

Mesh:

Substances:

Year:  2015        PMID: 26586646     DOI: 10.1016/j.tube.2015.09.005

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  19 in total

Review 1.  Skin microbiota-host interactions.

Authors:  Y Erin Chen; Michael A Fischbach; Yasmine Belkaid
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

Review 2.  Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria.

Authors:  Elizabeth Ann Misch; Christopher Saddler; James Muse Davis
Journal:  Curr Infect Dis Rep       Date:  2018-03-19       Impact factor: 3.725

Review 3.  The Mycobacterium tuberculosis capsule: a cell structure with key implications in pathogenesis.

Authors:  Rainer Kalscheuer; Ainhoa Palacios; Itxaso Anso; Javier Cifuente; Juan Anguita; William R Jacobs; Marcelo E Guerin; Rafael Prados-Rosales
Journal:  Biochem J       Date:  2019-07-18       Impact factor: 3.857

Review 4.  The Goldilocks model of immune symbiosis with Mycobacteria and Candida colonizers.

Authors:  Richard T Robinson; Anna R Huppler
Journal:  Cytokine       Date:  2017-05-29       Impact factor: 3.861

Review 5.  Mannose-capped lipoarabinomannan in Mycobacterium tuberculosis pathogenesis.

Authors:  Joanne Turner; Jordi B Torrelles
Journal:  Pathog Dis       Date:  2018-06-01       Impact factor: 3.166

6.  In vivo virulence of Mycobacterium tuberculosis depends on a single homologue of the LytR-CpsA-Psr proteins.

Authors:  S Malm; S Maaß; U E Schaible; S Ehlers; S Niemann
Journal:  Sci Rep       Date:  2018-03-02       Impact factor: 4.379

7.  PGL I expression in live bacteria allows activation of a CD206/PPARγ cross-talk that may contribute to successful Mycobacterium leprae colonization of peripheral nerves.

Authors:  Chyntia Carolina Díaz Acosta; André Alves Dias; Thabatta Leal Silveira Andrezo Rosa; Leonardo Ribeiro Batista-Silva; Patricia Sammarco Rosa; Thiago Gomes Toledo-Pinto; Fabrício da Mota Ramalho Costa; Flávio Alves Lara; Luciana Silva Rodrigues; Katherine Antunes Mattos; Euzenir Nunes Sarno; Patrícia Torres Bozza; Christophe Guilhot; Márcia de Berrêdo-Pinho; Maria Cristina Vidal Pessolani
Journal:  PLoS Pathog       Date:  2018-07-06       Impact factor: 6.823

Review 8.  Lipoarabinomannan in Active and Passive Protection Against Tuberculosis.

Authors:  Margarida Correia-Neves; Christopher Sundling; Andrea Cooper; Gunilla Källenius
Journal:  Front Immunol       Date:  2019-09-11       Impact factor: 7.561

Review 9.  Immunological consequences of strain variation within the Mycobacterium tuberculosis complex.

Authors:  Leopold D Tientcheu; Anastasia Koch; Mthawelenga Ndengane; Genevieve Andoseh; Beate Kampmann; Robert J Wilkinson
Journal:  Eur J Immunol       Date:  2017-02-24       Impact factor: 5.532

10.  Characterization of the Antigenic Heterogeneity of Lipoarabinomannan, the Major Surface Glycolipid of Mycobacterium tuberculosis, and Complexity of Antibody Specificities toward This Antigen.

Authors:  Alok Choudhary; Deendayal Patel; William Honnen; Zhong Lai; Raja Sekhar Prattipati; Ruixiang Blake Zheng; Ying-Chao Hsueh; Maria Laura Gennaro; Alfred Lardizabal; Blanca I Restrepo; Moncerrato Garcia-Viveros; Maju Joe; Yu Bai; Ke Shen; Kamar Sahloul; John S Spencer; Delphi Chatterjee; Tobias Broger; Todd L Lowary; Abraham Pinter
Journal:  J Immunol       Date:  2018-04-02       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.